Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. They leverage their proprietary Kinase Switch Control Inhibitor platform to develop a diverse portfolio of innovative medicines. Their lead approved product, QINLOCK® (ripretinib), is a switch-control kinase inhibitor for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Serves as the corporate headquarters, housing executive leadership, research and development laboratories, clinical operations, and administrative functions.
Modern office and laboratory facilities situated in a prominent biotech hub, designed to foster innovation and collaboration.
Characterized by a science-driven, patient-focused, and collaborative environment. Employees are typically mission-oriented, dedicated to advancing oncology treatments.
Strategically located in the Greater Boston area, a leading global center for biotechnology, providing access to talent, research institutions, and industry partners.
Deciphera Pharmaceuticals supports its global operations through its U.S. headquarters in Waltham, MA, and its European headquarters in Zug, Switzerland. These key locations facilitate worldwide clinical trial management, drug discovery, regulatory affairs, and commercialization efforts for its oncology therapeutics, particularly focusing on North American and European markets.
200 Smith Street
Waltham
Massachusetts
United States
Address: Gubelstrasse 11, 6300 Zug, Switzerland
To manage and expand the commercialization of QINLOCK® and future pipeline products within the European market, and to oversee regional clinical trial activities.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Deciphera Pharmaceuticals' leadership includes:
Deciphera Pharmaceuticals has been backed by several prominent investors over the years, including:
In the past year, Deciphera Pharmaceuticals has seen limited publicly announced changes at the top executive level. Key appointments in the preceding period, such as the Chief Business Officer in mid-2023, continue to shape the company's strategic direction.
Discover the tools Deciphera Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Deciphera Pharmaceuticals most commonly uses the email format [first_initial][last]@deciphera.com. Other variations might exist but this is the primary structure observed.
flast@deciphera.com
Format
jdoe@deciphera.com
Example
85%
Success rate
Deciphera Pharmaceuticals • May 7, 2024
Deciphera announced its financial results for Q1 2024, highlighting QINLOCK net product revenue of $45.8 million and progress in its clinical pipeline, including the ongoing NDA review for vimseltinib....more
Deciphera Pharmaceuticals • April 1, 2024
The FDA accepted Deciphera's NDA for vimseltinib for the treatment of patients with tenosynovial giant cell tumor (TGCT) and granted Priority Review, with a PDUFA target action date of August 28, 2024....more
Deciphera Pharmaceuticals • February 15, 2024
Deciphera reported its financial results for Q4 and full-year 2023, emphasizing strong QINLOCK sales and pipeline advancements, including the submission of the NDA for vimseltinib....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Deciphera Pharmaceuticals, are just a search away.